



# Test Definition: MCSTP

MayoComplete Solid Tumor Panel,  
Next-Generation Sequencing, Tumor

## Overview

### Useful For

Assisting in tumor profiling for diagnosis, predicting prognosis, and identifying targeted therapies for the treatment and management of patients with solid tumors

Identifying somatic alterations including single nucleotide variants, small deletions/insertions, gene amplifications, homozygous gene deletions, fusions, and splice variants in genes known to be associated with the tumorigenesis of solid tumors

Assessment of microsatellite instability and tumor mutational burden status

### Genetics Test Information

This test uses targeted next-generation sequencing to estimate tumor mutational burden and detect microsatellite instability, sequence variants, gene amplifications, homozygous gene deletions, fusions, and specific transcript variants in solid tumors. This panel includes a DNA subpanel for the detection of sequence alterations in 515 genes, amplification of 96 genes, homozygous deletion of 133 genes, as well as an RNA subpanel for the detection of fusions involving 55 genes and specific splice variants involving *EGFR*, *AR*, and *MET*. Sequence variants and copy number changes are concomitantly interpreted to evaluate for complete inactivation of 31 tumor suppressor genes. See [Genes Interrogated by MayoComplete Solid Tumor Panel](#) for details regarding genes interrogated by this test.

This test is performed to evaluate for somatic (ie, tumor-specific) alterations within the genes listed. Although germline (ie, inherited) alterations may be detected, this test cannot distinguish between germline and somatic alterations with absolute certainty. Follow-up germline testing using whole blood can be performed for confirmation of suspected clinically relevant germline alterations. Germline testing should be performed along with genetic counselling.

### Additional Tests

Test Id	Reporting Name	Available Separately	Always Performed
SLIRV	Slide Review in MG	No, (Bill Only)	Yes

### Testing Algorithm

When this test is ordered, slide review will always be performed at an additional charge to ensure specimen adequacy.

### Special Instructions

- [Genes Interrogated by MayoComplete Solid Tumor Panel](#)
- [MayoComplete Solid Tumor Panel DNA Panel Excluded DNA Regions](#)

### Highlights

### Method Name

---

Sequence Capture and Targeted Next-Generation Sequencing (NGS)

**NY State Available**

Yes

**Specimen****Specimen Type**

Varies

**Ordering Guidance**

Multiple oncology (cancer) gene panels are available. For more information see [Hematology, Oncology, and Hereditary Test Selection Guide](#).

**Necessary Information**

**A pathology report (final or preliminary), at minimum containing the following information, must accompany specimen for testing to be performed:**

1. Patient name
2. Block number-must be on all blocks, slides, and paperwork (can be handwritten on the paperwork)
3. Tissue collection date
4. Source of the tissue
5. Pathologic diagnosis (final or preliminary)

**Specimen Required**

**This assay requires at least 20% tumor nuclei. However, 40% tumor is preferred.**

-Preferred amount of tumor area: 432 mm<sup>2</sup> tissue on up to 20 unstained slides

-Minimum amount of tumor area: 72 mm<sup>2</sup> tissue on up to 20 unstained slides

-Tissue fixation: 10% neutral buffered formalin, not decalcified

-For this test, at least 4.6 mm x 4.6 mm areas on 20 unstained slides is preferred: this is approximately equivalent to 432 mm<sup>2</sup>. The minimum acceptable area is 1.9 mm x 1.9 mm on 20 unstained slides: approximately equivalent to 72 mm<sup>2</sup>.

**Preferred:** Submit 3, if available, or 2 of the following specimens.

**Acceptable:** Submit **at least one** of the following specimens.

**Specimen Type:** Tissue block

**Collection Instructions:** Submit a formalin-fixed, paraffin-embedded tissue block with acceptable amount of tumor tissue.

**Specimen Type:** Tissue slide

**Slides:** 1 Hematoxylin and eosin-stained and 20 unstained

**Collection Instructions:**

Submit the followings slides:

1 Slide stained with hematoxylin and eosin

AND

20 Unstained, nonbaked slides with 5-micron thick sections of the tumor tissue.

**Note:** The total amount of required tumor nuclei can be obtained by scraping up to 20 slides from the same block.

**Additional Information:** Unused unstained slides will not be returned.

**Specimen Type:** Cytology slide (Diff-Quik, Pap-stained direct smears, or ThinPrep)

**Slides:** 2 to 6 Slides

**Collection Instructions:** Submit at least 2 slides, stained and coverslipped, with a total of 10,000 nucleated cells (preferred) or at least 2000 nucleated cells (minimum) per slide.

**Note:** Glass coverslips are preferred; plastic coverslips are acceptable but will result in longer turnaround times.

**Additional Information:** Cytology slides will not be returned. An image of the slides will be stored per regulatory requirements.

## Forms

If not ordering electronically, complete, print, and send a [Oncology Test Request](#) (T729) with the specimen.

## Specimen Minimum Volume

See Specimen Required

## Reject Due To

All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.

## Specimen Stability Information

Specimen Type	Temperature	Time	Special Container
Varies	Ambient (preferred)		
	Refrigerated		

## Clinical & Interpretive

### Clinical Information

Targeted cancer therapies are defined as antibody or small molecule drugs that block the growth and spread of cancer by interfering with specific cell molecules involved in tumor growth and progression. Multiple targeted therapies have been approved by the US Food and Drug Administration for the treatment of solid tumor malignancies. Molecular genetic profiling is often needed to identify targets amenable to targeted therapies and to minimize treatment costs and therapy-associated risks. Tumor mutational burden and microsatellite instability status are increasingly important biomarkers for determining effective immunotherapeutic treatment options for patients with solid tumors.(1,2)

In addition to providing therapeutic insight, molecular profiling of tumors often provides prognostic and diagnostic information. Next-generation sequencing is an accurate, cost-effective method to identify variants across numerous genes known to be associated with response or resistance to specific targeted therapies. This test is a single assay that uses formalin-fixed paraffin-embedded tissue or cytology specimens to assess for Tier I and Tier II variants in 515 genes

---

known to be associated with solid tumors.(3)

**Reference Values**

An interpretive report will be provided.

**Interpretation**

The interpretation of molecular biomarker analysis includes an overview of the results and the associated diagnostic, prognostic, and therapeutic implications.

**Cautions**

Test results should be interpreted in the context of clinical, tumor sampling, histopathological, and other laboratory data. If results obtained do not match other clinical or laboratory findings, contact the laboratory for discussion. Misinterpretation of results may occur if the information provided is inaccurate or incomplete.

Reliable results are dependent on adequate specimen collection and processing. This test has been validated on cytology slides and formalin-fixed, paraffin-embedded tissues; other types of fixatives are discouraged. Treatment of tissues, such as decalcification, may cause polymerase chain reaction failure.

To ensure accuracy, this test will be performed on cases that are estimated by a pathologist to have 20% or more tumor cells, however, for optimal performance of this assay, a tumor purity of 40% is recommended.

This test does not differentiate between somatic and germline alterations. Additional testing may be necessary to clarify the significance of results if there is a potential hereditary risk.

This test does not detect large structural variants, large copy number changes, or deletions-insertions greater than approximately 20 base pairs in size.

Rare variants (ie, polymorphisms) may be present that could lead to false-negative or false-positive results.

A negative (ie, wildtype) result does not rule out the presence of an alteration that may be present but below the limits of detection of this assay.

The presence or absence of a variant or rearrangement may not be predictive of response to therapy in all patients.

A list of genomic regions in the DNA panel that have insufficient coverage to reliably detect single nucleotide variants and small deletions/insertions are listed in [MayoComplete Solid Tumor Panel DNA Panel Excluded DNA Regions](#).

**Supportive Data****Performance Characteristics**

Verification studies demonstrated concordance between this test and the reference method for detection of single nucleotide variants (SNV) and deletions-insertions (delins) in 98.8% (503/509) and 98.6% (294/298) of variants, respectively. Detection accuracy of delins was 99.3% (277/279) in variants 1 to 10 base pairs (bp) in size, 93.3% (14/15) in variants 11 to 20 bp in size, and 75.0% (3/4) in variants greater than 20 bp in size.

The limit of detection for calling a somatic variant (SNV and small delins) is 2% variant allele frequency (VAF) for regions having at least 150X median exon coverage depth. Gene amplification and homozygous gene deletion detection are most accurate at 40% or more tumor purity. For gene amplifications, the overall sensitivity was 100% (79/79), specificity was 100% (11,249/11,249), and accuracy was 100% (11,328/11,328). For homozygous gene deletion the overall sensitivity was 95.1% (116/122), specificity was 99.99% (15,570/15,572), and accuracy was 99.9% (15,686/15,696). For bi-allelic inactivation, the overall sensitivity was 100% (140/140), specificity was 100% (3,518/3,518), and accuracy was 100% (3,658/3,658).

Of the 130 microsatellite sites available for evaluation in this assay, at least 20% of sites are required to be unstable to classify the case as MSI-High. Microsatellite instability (MSI) evaluation is most accurate at a tumor purity of 40% or more, although, highly unstable tumors may be detectable at 20% tumor. During verification studies, 100% concordance was observed between this test and orthogonal methods used to detect MSI status.

Tumor mutational burden (TMB) was measured as mutations per megabase (Mb) for regions with greater than 50X coverage. When TMB scores were classified as TMB-Low (<10 mut/Mb) or TMB-High (> or =10 mut/Mb), 83.3% (50/60) concordance was achieved between this test and orthogonal assays detecting TMB status. TMB values are most accurate at greater than or equal to 40% tumor purity.

Fusions are detected with the presence of 3 or more supporting reads passing pipeline filters and splice variants with 10 or more supporting reads. For fusions and splice variants, the overall sensitivity was 98.0% (151/154), specificity was 94.8% (91/96), and accuracy was 96.8% (242/250). Fusion and splice variant detection are most accurate at greater than or equal to 20% tumor purity.

Table. Analytical Sensitivity

Variant type	Threshold for positivity	Recommended tumor purity
SNV	> or =2% VAF with >150X median exon coverage	> or =20%
DELIN	> or =2% VAF, < or =20 bp	> or =20%
Gene amplification*	N/A	> or =40%
Homozygous gene deletion*	N/A	> or =40%
MSI status	> or =20% sites unstable= MSI-H	> or =40%
TMB status	> or =10 variants per megabase= TMB-High	> or =40%
Fusion	> or =3 supporting reads	> or =20%
Splice variant	> or =10 supporting reads	> or =20%

\*Gene amplifications and homozygous deletions will be called by the bioinformatic pipeline and subjected to expert manual review to optimize sensitivity and specificity.

## Clinical Reference

1. Strom SP. Current practices and guidelines for clinical next-generation sequencing oncology testing. *Cancer Biol Med.* 2016;13(1):3-11. doi:10.28092/j.issn.2095-3941.2016.0004
2. Spurr L, Li M, Alomran N, et al. Systematic pan-cancer analysis of somatic allele frequency. *Sci Rep.* 2018;8(1):7735.

---

Published 2018 May 16. doi:10.1038/s41598-018-25462-0

3. US Food and Drug Administration (FDA): Table of Pharmacogenomic Biomarkers in Drug Labeling. FDA; Updated February 10, 2023, Accessed August 1, 2023. Available at [www.fda.gov/drugs/science-and-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling](http://www.fda.gov/drugs/science-and-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling)
4. Jia Y, Xie Z, Li H. Intergenically spliced chimeric RNAs in cancer. *Trends Cancer*. 2016;2(9):475-482. doi:10.1016/j.trecan.2016.07.006
5. Jo VY, Fletcher CDM. WHO classification of soft tissue tumours: an update based on the 2013. 4th ed. *Pathology*. 2014;46(2):95-104. doi:10.1097/PAT.0000000000000050
6. Fletcher CDM. The evolving classification of soft tissue tumours - an update based on the new 2013 WHO classification. *Histopathology*. 2014;64(1):2-11. doi:10.1111/his.12267
7. Quesada J, Amato R. The molecular biology of soft-tissue sarcomas and current trends in therapy. *Sarcoma*. 2012;2012:849456. doi:10.1155/2012/849456
8. Podnar J, Deiderick H, Huerta G, Hunicke-Smith S. Next-generation sequencing RNA-seq library construction. *Curr Protoc Mol Biol*. 2014;106:4.21.1-19. doi:10.1002/0471142727.mb0421s106
9. Mertens F, Tayebwa J. Evolving techniques for gene fusion detection in soft tissue tumours. *Histopathology*. 2014;64(1):151-162. doi:10.1111/his.12272
10. Al-Zaid T, Wang WL, Somaiah N, Lazar AJ. Molecular profiling of sarcomas: new vistas for precision medicine. *Virchows Arch*. 2017;471(2):243-255
11. Gao Q, Liang WW, Foltz SM, et al. Driver fusions and their implications in the development and treatment of human cancers. *Cell Rep*. 2018;23(1):227-238e3. doi:10.1016/j.celrep.2018.03.050
12. Lam SW, Cleton-Jansen AM, Cleven AHG, et al. Molecular analysis of gene fusions in bone and soft tissue tumors by anchored multiplex PCR-based targeted next-generation sequencing. *J Mol Diagn*. 2018;20(5):653-663. doi:10.1016/j.jmoldx.2018.05.007
13. Roy A, Kumar V, Zorman B, et al. Recurrent internal tandem duplications of BCOR in clear cell sarcoma of the kidney. *Nat Commun*. 2015;6:8891. doi:10.1038/ncomms9891
14. Marino-Enriquez A, Lauria A, Przybyl J, et al. BCOR internal tandem duplication in high-grade uterine sarcomas. *Am J Surg Pathol*. 2018;42(3):335-341. doi:10.1097/PAS.0000000000000993
15. Marcus L, Lemery SJ, Keegan P, Pazdur R. FDA Approval Summary: Pembrolizumab for the treatment of microsatellite instability-high solid tumors. *Clin Cancer Res*. 2019;25(13):3753-3758. doi:10.1158/1078-0432.CCR-18-4070

## Performance

### Method Description

Next-generation sequencing is performed to estimate tumor mutational burden and microsatellite instability status, somatic sequence variants, gene amplifications, homozygous gene deletions, gene fusions, and specific transcript variants in solid tumors. This test detects single nucleotide variants and small insertions and deletion within 515 genes, amplification of 96 genes, homozygous deletions in 133 genes, fusions involving 55 genes, and splice variants involving *EGFR*, *AR*, and *MET*. (Instruction manual: TruSight Oncology 500 High-Throughput. Illumina; 11/2020)

See [Genes Interrogated by MayoComplete Solid Tumor Panel](#) for details regarding genes interrogated by this test.

**PDF Report**

Supplemental

**Day(s) Performed**

Varies

**Report Available**

14 to 21 days

**Specimen Retention Time**Tissue blocks: Unused portions of blocks will be returned; Tissue slides: Unused slides are stored for at least 5 years;  
Extracted DNA/RNA: 3 months**Performing Laboratory Location**

Mayo Clinic Laboratories - Rochester Main Campus

**Fees & Codes****Fees**

- Authorized users can sign in to [Test Prices](#) for detailed fee information.
- Clients without access to Test Prices can contact [Customer Service](#) 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact [Customer Service](#).

**Test Classification**

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

**CPT Code Information**

81459

88381-Microdissection, manual

**LOINC® Information**

Test ID	Test Order Name	Order LOINC® Value
MCSTP	MayoComplete Solid Tumor Panel	73977-1

Result ID	Test Result Name	Result LOINC® Value
610425	Result	82939-0
610426	Interpretation	69047-9
610427	Additional Information	48767-8
610428	Clinical Trials	82786-5
610429	Variants of Uncertain Significance	93367-1
610430	Specimen	31208-2

## Test Definition: MCSTP

MayoComplete Solid Tumor Panel,  
Next-Generation Sequencing, Tumor

610431	Tissue ID	80398-1
610432	Method	85069-3
610433	Disclaimer	62364-5
610434	Released By	18771-6